Market Cap 9.93B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.97%
Debt to Equity Ratio -4.46
Volume 537,000
Avg Vol 515,852
Day's Range N/A - N/A
Shares Out 60.97M
Stochastic %K 91%
Beta 0.41
Analysts Strong Sell
Price Target $220.06

Latest News on ASND

FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 2 days ago

FDA Accepts TransCon® CNP NDA for Priority Review


Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 4 weeks ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript


Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 4 weeks ago

Ascendis Pharma Reports First Quarter 2025 Financial Results


Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 4 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript


Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 4 months ago

Ascendis Pharma: Danish Blockbuster Hunter


Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:53 PM EST - 7 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript


Ascendis Pharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 7 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results


Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 19, 2024, 8:16 PM EDT - 9 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs


Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 18, 2024, 4:04 PM EDT - 9 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs


Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 5, 2024, 1:30 AM EDT - 9 months ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa


Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 9:41 PM EDT - 9 months ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript


Ascendis Pharma Reports Second Quarter 2024 Financial Results

Sep 3, 2024, 5:04 PM EDT - 9 months ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results


FDA approves Ascendis Pharma's hormone disorder therapy

Aug 12, 2024, 7:23 AM EDT - 10 months ago

FDA approves Ascendis Pharma's hormone disorder therapy